Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients Germann N; Goffinet F; Goldwasser FAnn Oncol 2004[Jan]; 15 (1): 146-50BACKGROUND: Anthracyclines are essential for the treatment of malignancies observed in pregnant patients. Knowledge of the potential side-effects of chemotherapy on the developing fetus is essential for patient counseling. PATIENTS AND METHODS: We collected information concerning patients treated with anthracyclines during pregnancy from a review of literature between 1976 and 2001 and our experience. The events analyzed were malformations, fetal death and spontaneous abortion. A chi(2) test with a Yates correction was used to compare the distribution of severe events. RESULTS: A total of 160 patient pregnancies were analyzed. The fetal outcome was frequently normal (73%). Abnormalities included malformations (3%), fetal death (9%), spontaneous abortion (3%), fetal complications (8%) and prematurity (6%). Fetal death was often directly consecutive to maternal death (40%). Unfavorable fetal outcome was significantly more frequent in leukemia patients (P = 0.001). In patients with solid tumors, the first trimester was significantly associated with more complications (P = 0.029). The risk of severe fetal toxicity was increased 30-fold when the dose of doxorubicin per cycle exceeded 70 mg/m(2) (P = 0.037). CONCLUSIONS: Anthracyclines may induce embryo-fetal toxicity. Nevertheless the risk seems low, especially after the first trimester and using doses of doxorubicin below 70 mg/m(2).|Abnormalities, Drug-Induced/*classification/epidemiology[MESH]|Abortion, Spontaneous[MESH]|Adolescent[MESH]|Adult[MESH]|Anthracyclines/*adverse effects/therapeutic use[MESH]|Daunorubicin/administration & dosage/therapeutic use[MESH]|Doxorubicin/administration & dosage/therapeutic use[MESH]|Embryonic and Fetal Development/drug effects[MESH]|Female[MESH]|Fetal Death[MESH]|Humans[MESH]|Infant, Newborn[MESH]|Infant, Premature[MESH]|Maternal-Fetal Exchange[MESH]|Pregnancy[MESH]|Pregnancy Complications, Neoplastic/classification/*drug therapy[MESH]|Pregnancy Trimesters[MESH]|Registries[MESH]|Retrospective Studies[MESH]|Risk Factors[MESH] |
